Piper Sandler downgraded Allakos (ALLK) to Neutral from Overweight with a price target of 30c, down from $7.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLK:
- Allakos to discontinue further clinical development of AK006, cut workforce 75%
- Allakos Restructures Amid AK006 Program Discontinuation
- Allakos Restructures Amid AK006 Discontinuation and Layoffs
- Allakos announces results from its Phase 1 trial of AK006
- JMP Securities healthcare analysts hold an analyst/industry conference call